Earnings Data
Report Date
Aug 19, 2026TBA (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.07Last Year’s EPS
-0.23Same Quarter Last Year
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call presented a balanced picture: the company executed its strategic repositioning (BICO 2.0), strengthened its cash position through a EUR 40m bond issuance, reduced debt and demonstrated a clear Q4 recovery with strong margins and Biosero momentum. However, full-year financials were weak (organic sales -8%, adjusted EBITDA only SEK 5m, Lab Automation full-year decline -26% and negative EBITDA), and the business faced notable macro headwinds (US academia funding cuts, FX pressure and cautious CapEx). Product launches, partnerships and AI-enabled offerings provide a foundation for growth, but near-term performance still reflects industry and legacy operational challenges.Company Guidance
Improved Cash Position and Successful Capital Raise
Cash reserves at year-end of SEK 1.282 billion; issued senior secured bonds on Jan 28, 2026 with nominal value EUR 40 million (4-year tenure, 3M Euribor + 5.9%, issued at 96.81%). After settling outstanding convertible debt (~SEK 1.008 billion), pro forma cash position is estimated at ~SEK 670 million to support growth, R&D and bolt-on acquisitions.
Quarter 4 Profitability Recovery
Group Q4 adjusted EBITDA of SEK 56 million representing a 13% adjusted EBITDA margin and operating cash flow of SEK 52 million, demonstrating a stronger quarter and improved profitability versus the full-year run rate.
Life Science Solutions Solid Performance
Full-year sales SEK 1.108 billion with organic sales growth of +1% and adjusted EBITDA SEK 83 million (8% margin). Q4 for the business area delivered SEK 326 million in sales and a robust 15% adjusted EBITDA margin (SEK 49 million).
Lab Automation Turnaround in Q4 and Biosero Momentum
Lab Automation closed the year strongly with Q4 sales SEK 125 million and organic sales growth +15%; Q4 adjusted EBITDA SEK 18 million (15% margin). Biosero finished the year with double-digit growth in Q4 after operational improvements and new leadership, indicating a successful turnaround trajectory.
Strategic Portfolio Focus and Cost Discipline
Management reports execution of BICO 2.0: a focused portfolio on lab automation, structural cost reductions and tighter R&D governance (gate-stage model). Net working capital at 13% of L12M sales (targeting ~20% long-term) and continued emphasis on expense management.
Product and Commercial Momentum (AI & Partnerships)
Multiple product launches at SLAS including Biosero's GoSimple (partnerships with Sartorius and Becton Dickinson) and an early-access assistive AI toolset in Green Button Go (natural language workflow creation). Several collaboration leads from SLAS and emphasis on software/AI-heavy R&D pipeline.
Customer Proof Points for Productivity Gains
Customer example (Top-20 pharma): downstream process and assay development time reduced 75%, equipment capacity increased 400%, and scientist productivity reported at 200% using BICO lab automation and Green Button Go, demonstrating high value proposition to pharma customers.
DE:49Z Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DE:49Z Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 29, 2026 | €1.84 | €1.80 | -2.39% |
Feb 18, 2026 | €1.59 | €1.78 | +12.41% |
Nov 04, 2025 | €2.25 | €2.21 | -1.96% |
Aug 19, 2025 | €3.13 | €2.43 | -22.46% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does BICO Group AB Class B (DE:49Z) report earnings?
BICO Group AB Class B (DE:49Z) is schdueled to report earning on Aug 19, 2026, TBA (Confirmed).
What is BICO Group AB Class B (DE:49Z) earnings time?
BICO Group AB Class B (DE:49Z) earnings time is at Aug 19, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of BICO Group AB Class B stock?
The P/E ratio of BICO Group AB Class B is N/A.
What is DE:49Z EPS forecast?
DE:49Z EPS forecast for the fiscal quarter 2026 (Q2) is -0.07.